In this presentation, Stephen J. Schuster, MD, examines a complex population comprising “double refractory” patients who either do not respond to the current front-line treatments rituximab and alkylating agent-based chemotherapy, or for whom these agents lose efficacy. Dr. Schuster then explores two therapeutic approaches to this population, P13 kinase inhibition (Idelalisib, Copanlisib) and CD19-directed CAR T cell therapy. As the lead investigator of the tisagenlecleucel study (UPCC 13413) in patients with CD19+B Cell Lymphoma at the Abramson Cancer Center, Dr Schuster offers his insight to a discussion of this trial, as well.
Enrolling Clinical Trials: Umbilical Cord Blood Transplantation vs Haploidentical Transplantation for Patients with Hematological Malignancies
Connect on Doximity
Dr Schuster’s Profile